Integrity Alliance LLC. Acquires 3,186 Shares of Cencora, Inc. $COR

Integrity Alliance LLC. raised its holdings in Cencora, Inc. (NYSE:COR) by 54.3% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 9,053 shares of the company’s stock after purchasing an additional 3,186 shares during the period. Integrity Alliance LLC.’s holdings in Cencora were worth $2,518,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in COR. Price T Rowe Associates Inc. MD boosted its stake in shares of Cencora by 8.9% in the first quarter. Price T Rowe Associates Inc. MD now owns 9,647,310 shares of the company’s stock valued at $2,682,821,000 after buying an additional 787,858 shares during the period. Wellington Management Group LLP increased its stake in Cencora by 7.2% during the 1st quarter. Wellington Management Group LLP now owns 5,421,262 shares of the company’s stock worth $1,507,599,000 after acquiring an additional 363,402 shares during the period. Boston Partners lifted its position in shares of Cencora by 8.1% during the 1st quarter. Boston Partners now owns 5,411,193 shares of the company’s stock valued at $1,505,984,000 after acquiring an additional 404,093 shares during the period. Invesco Ltd. lifted its position in shares of Cencora by 42.1% during the 1st quarter. Invesco Ltd. now owns 4,607,964 shares of the company’s stock valued at $1,281,429,000 after acquiring an additional 1,364,433 shares during the period. Finally, Goldman Sachs Group Inc. grew its holdings in shares of Cencora by 9.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,711,281 shares of the company’s stock worth $475,890,000 after purchasing an additional 154,311 shares in the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.

Insider Buying and Selling at Cencora

In related news, CEO Robert P. Mauch sold 4,968 shares of the business’s stock in a transaction on Friday, July 18th. The stock was sold at an average price of $294.11, for a total transaction of $1,461,138.48. Following the sale, the chief executive officer owned 42,351 shares in the company, valued at $12,455,852.61. The trade was a 10.50% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Chairman Steven H. Collis sold 14,578 shares of the stock in a transaction dated Tuesday, July 22nd. The shares were sold at an average price of $292.67, for a total value of $4,266,543.26. Following the completion of the transaction, the chairman owned 309,913 shares of the company’s stock, valued at $90,702,237.71. This represents a 4.49% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 34,125 shares of company stock worth $9,993,789. 10.80% of the stock is currently owned by company insiders.

Cencora Stock Down 0.8%

Shares of NYSE COR opened at $296.38 on Thursday. The company has a market cap of $57.46 billion, a price-to-earnings ratio of 30.49, a PEG ratio of 1.42 and a beta of 0.62. The company has a current ratio of 0.90, a quick ratio of 0.53 and a debt-to-equity ratio of 3.64. Cencora, Inc. has a 12 month low of $218.65 and a 12 month high of $309.35. The stock has a 50-day moving average price of $292.98 and a two-hundred day moving average price of $284.73.

Cencora (NYSE:COR) last announced its quarterly earnings results on Wednesday, August 6th. The company reported $4.00 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.79 by $0.21. The company had revenue of $80.66 billion for the quarter, compared to analyst estimates of $80.34 billion. Cencora had a net margin of 0.60% and a return on equity of 267.36%. The firm’s revenue was up 8.7% on a year-over-year basis. During the same period in the previous year, the firm posted $3.34 EPS. As a group, analysts forecast that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Friday, August 15th were issued a dividend of $0.55 per share. The ex-dividend date of this dividend was Friday, August 15th. This represents a $2.20 annualized dividend and a dividend yield of 0.7%. Cencora’s dividend payout ratio (DPR) is 22.63%.

Analyst Upgrades and Downgrades

COR has been the subject of several recent analyst reports. Jefferies Financial Group upped their price objective on shares of Cencora from $275.00 to $300.00 and gave the stock a “hold” rating in a research report on Monday, June 30th. Morgan Stanley set a $330.00 target price on shares of Cencora and gave the company an “equal weight” rating in a research report on Wednesday, July 16th. Finally, Wells Fargo & Company increased their price target on shares of Cencora from $337.00 to $354.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 13th. Nine research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $311.25.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.